ArticleCureus2026
Estimation of Colistin Resistance Among Multidrug-Resistant Gram-Negative Bacilli: An Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe rise in antimicrobial resistance, particularly among Gram-negative bacilli (GNB), poses a significant threat to global public health. Colistin, a polymyxin antibiotic, has re-emerged as a last-resort treatment against multidrug-resistant Gram-negative bacilli (MDR-GNB). However, increasing colistin resistance has become a major concern, especially in clinical settings where treatment options are limited.
aimTo estimate the prevalence of colistin resistance among MDR-GNB and to compare the performance of three phenotypic methods, broth microdilution (BMD), colistin broth disk elution (CBDE), and colistin agar test (CAT), for detecting colistin resistance.
methodsThis observational study was conducted over a period of one year at a tertiary care hospital in Gwalior, Madhya Pradesh. A total of 100 MDR-GNB isolates were included as a convenience sample during the study period, which was considered adequate to estimate colistin resistance and evaluate the diagnostic performance of the testing methods. The isolates were screened for colistin susceptibility using BMD (gold standard), CBDE, and CAT as per Clinical and Laboratory Standards Institute (CLSI) guidelines. Diagnostic performance, including sensitivity, specificity, and categorical agreement, was assessed for CBDE and CAT in comparison with BMD.
resultsAmong 100 MDR Gram-negative isolates,
conclusionThe emergence of colistin-resistant MDR-GNB emphasizes the urgent need for accurate and accessible susceptibility testing. While BMD remains the reference standard, CBDE offers a practical and reliable alternative for routine laboratory use. Regular surveillance and rational use of colistin are essential to curb the spread of resistance and preserve the efficacy of this critical antimicrobial agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.